Eiko Lifesciences Ltd (EIKO) is currently trading at 51.44 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Eiko Lifesciences Limited specializes in manufacturing and exporting specialty chemicals and pharma intermediates, serving both Indian and global markets. Originally founded as Narendra Investments (Delhi) Limited, the company shifted to its current name and business focus in 2021, marking a significant transformation. Since commencing specialty and fine chemicals production in 2020, Eiko has rapidly scaled operations and expanded its brand and customer base, emerging as a fast-growing player in India. In 2022, Eiko launched new molecules targeting agrochemical intermediates, polymer science, and pharmaceuticals, showcasing its innovation capabilities. The company diversified into applications for agrochemical, personal care, and food industries in 2023, broadening its product range.

Over the past 52 weeks, Eiko Lifesciences Ltd has traded between a low of ₹43.00 and a high of ₹64.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Eiko Lifesciences Ltd has a market capitalization of approximately 74.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Eiko Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 74.44 Cr, Eiko Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Eiko Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Eiko Lifesciences Ltd is 15.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Eiko LifeSciences reported consolidated net profit after tax of Rs 3.07 crore for the half year ended 30 September 2026. This was Rs 67.01 lakh higher than Rs 2.40 crore in the corresponding half year of 2025.

Eiko Lifesciences used Rs 2.2183 crore in operating activities for the period ended September 30, 2026. Cash used in operations was Rs 1.2046 crore before Rs 1.0137 crore of net direct tax payments.

Eiko Lifesciences says its wholly owned subsidiary, Eiko Scientific Solutions LLP, will hold 50% of Oval Eiko Resources Private Limited. Oval Projects Engineering Limited is identified as the other 50% joint-venture partner.

Eiko LifeSciences reported revenue of ₹17.16 crore in Q1 FY2027. The company said this was 53% higher than the corresponding first quarter of FY2026.